Clinical Trials
Trial: FOCUS trial (TEVA)
Participating centers: UZ Brussel, CHR (Liège), Virga Jesse (Hasselt) and AZ St Jan (Brugge)
Target population: episodic and chronic migraine with previous inadequate response to prior preventive treatments
Intervention: monoclonal antibody against CGRP injection subcutaneously once per month for three months (placebo-controlled period), open-label use thereafter (until
available on the market)
Contact principal investigator: Prof. Dr J Versijpt (02 4763739), Prof. Dr D Magis (Liège), Dr A Van Dycke (Brugge) or Dr N De Klippel (Hasselt)